Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B
Open Access
- 23 August 2017
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 48 (3), E213-E221
- https://doi.org/10.1111/hepr.12972
Abstract
Aim The role of vitamin D in individuals with chronic hepatitis B (CHB) is unclear. We aimed to explore the association of baseline vitamin D level with genetic determinants and week‐104 treatment outcome in CHB patients. Methods Baseline serum 25‐hydroxycholecalciferol (25(OH)D) levels and genetic polymorphism within GC, DHCR7, and CYP2R1 were determined in stored serum of 560 patients who were enrolled into a multicenter, randomized, controlled study and completed 104 weeks of telbivudine monotherapy or telbivudine‐based optimized therapy. Virologic response was defined as hepatitis B virus DNA P < 0.001). The area under the curve of 25(OH)D to predict virologic response was 0.65 (P < 0.001; 95% confidence interval, 0.62–0.67). On multivariate analysis, 25(OH)D level was an independent predictor of virologic response, but not associated with hepatitis B envelope antigen (HBeAg) seroconversion or alanine aminotransferase (ALT) normalization. Conclusions Vitamin D insufficiency was highly prevalent in treatment‐naïve CHB patients in mainland China. Latitude and genetic determinants affect vitamin D status. Baseline vitamin D level can predict week‐104 virologic response, but not HBeAg seroconversion or ALT normalization.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2012ZX10002003)
- Natural Science Foundation of Guangdong Province (2016A030313550)
- Guangzhou Science and Technology Program key projects (201604020002)
This publication has 27 references indexed in Scilit:
- Vitamin D and Immune FunctionNutrients, 2013
- Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’BMC Infectious Diseases, 2013
- Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytesJournal of Hepatology, 2011
- Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis CJournal of Hepatology, 2011
- Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patientsWorld Journal of Gastroenterology, 2011
- Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants: a randomized clinical trialOsteoporosis International, 2010
- Common genetic determinants of vitamin D insufficiency: a genome-wide association studyThe Lancet, 2010
- Chronic hepatitis B: Update 2009Journal of Hepatology, 2009
- Genetic and Environmental Determinants of 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels in Hispanic and African AmericansJournal of Clinical Endocrinology & Metabolism, 2008
- Vitamin D DeficiencyThe New England Journal of Medicine, 2007